Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
76-90 of 4385 results
Ergomed acquires PharmInvent
Pharmaceutical services and drug development firm Ergomed has acquired European PharmInvent Services s.r.o. (PharmInvent), a European pharmacovigilance and regulatory services business.
Drug Research > Drug Discovery & Development > News
UK biopharmaceutical firm Kymab secures $100m of funding
By PBR Staff Writer
UK-based biopharmaceutical firm Kymab has secured $100m of funding to advance its pipeline of therapeutic human monoclonal antibodies.
Drug Research > Drug Discovery & Development > News
WuXi Biologics, Prima sign non-binding MOU for biologics development
WuXi Biologics, a WuXi AppTec group company, and Prima Biomed have signed a non-binding MOU to form a strategic biologics development and manufacturing partnership.
Drug Research > Drug Discovery & Development > News
Allergan acquires Chase Pharmaceuticals
Allergan has acquired Chase Pharmaceuticals, a clinical-stage biopharmaceutical firm engaged in the development of improved treatments for neurodegenerative disorders including Alzheimer's disease (AD).
Drug Research > Drug Discovery & Development > News
FDA scientists develop new mouse model for Zika studies
Scientists at the US Food and Drug Administration (FDA) have developed a new mouse model which may help in exploring the potential activity of Zika virus vaccines and therapeutics.
Drug Research > Drug Discovery & Development > News
PharmAkea, Celgene expand fibrotic disease therapy partnership
PharmAkea's three-year-old collaboration with Celgene to develop novel small-molecule therapies targeting fibrotic diseases has been extended nine months.
Drug Research > Drug Discovery & Development > News
TNK Therapeutics enters into binding term sheet to buy Virttu Biologics
Sorrento Therapeutics' subsidiary TNK Therapeutics has entered into a binding term sheet to acquire Virttu Biologics.
Drug Research > Drug Discovery & Development > News
Selexis, OSE partner to advance immunotherapies development for cancer diseases
Selexis and OSE Immunotherapeutics have signed two service agreements to advance development of immunotherapies for cancer and autoimmune diseases.
Drug Research > Drug Discovery & Development > News
Eagle Pharmaceuticals agrees to buy Arsia Therapeutics
Eagle Pharmaceuticals has agreed to acquire Arsia Therapeutics, an early-stage biotechnology firm founded by MIT professors Robert Langer and Alex Klibanov, along with Polaris Partners to improve the delivery of highly viscous protein therapeutics.
Drug Research > Drug Discovery & Development > News
Vitality files international PCT patent application for cannabinoid pharmaceuticals
Vitality Biopharma has filed an international PCT patent application in its development of a platform of cannabinoid pharmaceuticals.
Drug Research > Drug Discovery & Development > News
Sorrento Therapeutics acquires majority stake in Scilex
Sorrento Therapeutics has completed its acquisition of majority stake in Scilex Pharmaceuticals (SCILEX).
Drug Research > Drug Discovery & Development > News
UIC researchers identify new way to inhibit major cancer gene
By PBR Staff Writer
Researchers at the University of Illinois at Chicago in the US have discovered a monobody that can block the oncogene’s activity.
Drug Research > Drug Discovery & Development > News
Nestle invests $145m in biopharmaceutical firm Aimmune Therapeutics
By PBR Staff Writer
Nestle Health Science is investing $145m for a 15% stake in Aimmune Therapeutics, a clinical-stage biopharmaceutical firm which develops treatments for people with life-threatening food allergies.
Drug Research > Drug Discovery & Development > News
Researchers engineer antimicrobial peptide to kill bacteria
By PBR Staff Writer
A team of researchers has developed a new weapon intended for taking down bacteria that are becoming increasingly resistant to existing antibiotics.
Drug Research > Drug Discovery & Development > News
Turnstone Biologics raises $41.4m to advance cancer immunotherapy
By PBR Staff Writer
Canada-based oncolytic viral immunotherapies developer Turnstone Biologics has raised $41.4m in a Series B venture financing.
Drug Research > Drug Discovery & Development > News
76-90 of 4385 results